Allyx Therapeutics, Inc.
New Haven, US · Founded 2018 · Delaware corporation · 5 employees on LinkedIn · 4 known investors
Find your way into Allyx Therapeutics, Inc.
732 people in our graph share verified history with the Allyx Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Lyle McCullochunlockedknows Jennifer Gabler · together at Coopers & Lybrand (overlapped)
×4knows the team · via Coopers & Lybrand
×2knows the team · via Dartmouth College
×2knows the team · via Canaan Partners
×2knows the team · via Arthur D. Little
knows the team · via Dicom Grid
Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.
Founders & leadership
Allyx Therapeutics, Inc. was founded in 2018 by Paul Fonteyne, Stephen Strittmatter, Stephen Bloch, Timothy Siegert, and Tim Siegert, PhD.
PF
SS
Stephen StrittmatterinScientific Founder
SB
Stephen Blochin𝕏Co-founder · Chief Executive OfficerStephen Bloch is CEO and co-founder of Allyx Therapeutics. He previously spent over 23 years as a General Partner at Canaan Partners investing in healthcare companies, served as CEO of RMS (a radiology benefits management company) for 6 years, and worked as a pharmaceutical strategy consultant at Arthur D. Little.
TS
Timothy SiegertinCo-founder · Chief Operating Officer
TS
Tim Siegert, PhDCOO & Co-Founder
JG
Jennifer GablerinFinance ConsultantJennifer Gabler serves as an Executive Officer at Allyx Therapeutics. She previously held CFO positions at multiple venture-backed and biotech companies and co-founded Marlborough Street Partners, which provides strategic and operational services to investors and venture-funded enterprises.
Board
RA
GP
Investors · 4
Reported raises · per SEC filings
Form D private placements$39.6M disclosed across 4 rounds · 2021–2026
▶$26.4MraisedMay 2026 · 32 investors · BiotechnologyRule 506(b)
▶$26.4MraisedMay 2026 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Stephen BlochExecutive Officer, Director
- Stephen StrittmatterDirector
- Robert A BettigoleDirector
- Paul FonteyneDirector
- Gregory P HoDirector
- Timothy SiegertExecutive Officer
- Kevin L. RakinDirector
- Offering amount
- $30M
- Amount sold
- $26.4M
- Finders' fees
- $149.4K
- Placement agents
- Supervision Partners LLC
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedMar 2026 · 12 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMar 2026 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer GablerExecutive Officer
- Robert A BettigoleDirector
- Paul FonteyneDirector
- Gregory P HoDirector
- Stephen StrittmatterDirector
- Stephen BlochExecutive Officer, Director
- Timothy SiegertExecutive Officer
- Offering amount
- $4M
- Amount sold
- $3.3M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2023 · 11 investors · BiotechnologyRule 506(b)
▶$2.3MraisedFeb 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert A. BettigoleDirector
- Stephen StrittmatterDirector
- Paul FonteyneDirector
- Gregory P. HoDirector
- Timothy SiegertExecutive Officer
- Stephen BlochExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$7.6MraisedJun 2021 · 10 investors · BiotechnologyRule 506(b)
▶$7.6MraisedJun 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory P. HoDirector
- Robert A. BettigoleDirector
- Stephen StrittmatterExecutive Officer, Director
- Stephen BlochExecutive Officer, Director
- Timothy SiegertExecutive Officer
- Paul FonteyneDirector
- Offering amount
- $8M
- Amount sold
- $7.6M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Alloy14 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Amylyx14 shared keywordsAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
Exelixis13 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Altay Therapeutics10 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Alumis8 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Allyx Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $450K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Allyx Therapeutics, Inc. do?
- Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.
- Who founded Allyx Therapeutics, Inc.?
- Allyx Therapeutics, Inc. was founded by Paul Fonteyne, Stephen Strittmatter, Stephen Bloch, Timothy Siegert, Tim Siegert, PhD in 2018.
- Who are Allyx Therapeutics, Inc.'s investors?
- Allyx Therapeutics, Inc.'s investors include Elm Street Ventures, Spring Mountain Capital, Connecticut Innovations, WHIN.
- How much funding has Allyx Therapeutics, Inc. raised?
- Allyx Therapeutics, Inc. has disclosed $39.6M raised across 4 rounds.
- Where is Allyx Therapeutics, Inc. headquartered?
- Allyx Therapeutics, Inc. is headquartered in New Haven, US.